You are here: Industry Insights > leukemia

News List

FDA updates the label of Tasigna to reflect that certain patients with a type of leukemia may be eli worldpharmanews
December 25, 2017
The U.S. Food and Drug Administration today updated the product label for the cancer drug Tasigna (nilotonib) to include information for providers about how to discontinue the drug in certain patients.
Pfizer's Bosulif scores US green light in leukaemia sub-type pharmafile
December 22, 2017
Pfizer has atment of newly-diagnosed chronic phase Philadelphia chromosome-positive chronic myelogenous leukaemia in adult patients.revealed that its tyrosine kinase inhibitor Bosulif (bosutinib) has been awarded marketing authorisation from the FDA in t
New study reveals barrier in quality end-of-life care for leukemia patients biospectrumasia
December 14, 2017
Study suggests improving access to blood transfusions could increase hospice care use among patients with advanced leukemia
Amphivena Receives Orphan Drug Designation for AMV564, a Novel CD33/CD3 T-Cell Engagement Therapy firstwordpharma
November 30, 2017
Amphivena has received an orphan drug label from the US Food and drug administration, which is used for the treatment of AML's pilot compound, AMV564.
Leukemia & Lymphoma Society Funds $46 Million in New Research americanpharmaceuticacreview
November 22, 2017
The Leukemia & Lymphoma Society has committed an additional $46 million to fund the science at medical institutions around the world. LLS has invested more than $1 billion in cancer research in its nearly 70-year history.
Prostaglandin EI inhibits leukaemia stem cells europeanpharmaceuticalreview
September 27, 2017
Targeting leukemia stem cells in combination with standard chemotherapy may improve treatment for chronic myeloid leukemia…
Pfizer's leukaemia drug gets opposing regulatory decisions on either side of the Atlantic pharmafile
August 21, 2017
Pfizer has received a bittersweet bout of news as it emerges that its drug Besponsa (inotuzumab ozogamicin) has received approval in the US, but has been rejected in the UK.
FDA approves new treatment for adults with relapsed or refractory acute lymphoblastic leukemia worldpharmanews
August 18, 2017
The U.S. Food and Drug Administration today approved Besponsa (inotuzumab ozogamicin) for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).
FDA approves Celgene and Agios' acute myeloid leukaemia drug pharmafile
August 03, 2017
The FDA has given its approval for the commercialisation of Celgene and Agios Pharmaceutical’s Idhifa for the treatment of relapsed or refractory acute myeloid leukaemia (AML) in patients with an IDH2 mutation, it has emerged.
FDA approves new targeted treatment for acute myeloid leukemia europeanpharmaceuticalreview
August 03, 2017
The U.S. Food and Drug Administration has granted the approval of Idhifa to Celgene Corporation and RealTime IDH2 Assay to Abbott Laboratories…

Previous page 1 2 3 4 5 Next page